Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Bevacizumab Stories

2013-05-05 16:20:25

CAMBRIDGE, Mass., May 5, 2013 /PRNewswire/ -- The Angiogenesis Foundation released a new white paper, "Advocating for Improved Treatment and Outcomes for Wet Age-Related Macular Degeneration" (AMD). Wet AMD is the most common form of blindness in people 50 years or older in developed nations. The report is based on the Australian Wet Age-Related Macular Degeneration Coalition Expert Summit convened in Sydney, Australia last July by the Angiogenesis Foundation and Macular Degeneration...

2013-04-25 23:01:50

Preventive medicine may not be the panacea to reducing healthcare costs. Ponte Vedra Beach, Florida (PRWEB) April 25, 2013 This week´s top news story on HealthEconomics.Com related to yet another rejection by the National Institute for Health and Care Excellence (NICE) for Roche´s Avastin (bevacizumab) for advanced ovarian cancer. NICE is the agency tasked with appraising cost-effectiveness of medicines for use in the National Health Service for England and Wales. Issuing its...

2013-04-24 16:26:04

Trial Results to be Submitted For U.S. Marketing Approval Under FDA Fast Track Designation For Promising New Therapies AUSTIN, Texas, Apr. 24, 2013 /PRNewswire/ -- XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia. The patient was enrolled by Dr. Eric Roeland at UC San Diego's Moores Cancer Center. The study is...

2013-04-23 08:35:13

Among Newly Diagnosed Patients, Increasing Overall Survival is one of the Greatest Unmet Needs in ED-SCLC, According to a New Report from Decision Resources BURLINGTON, Mass., April 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the numerous therapies in clinical development for extensive-disease small-cell lung cancer (ED-SCLC), no emerging therapy is likely to replace...

2013-04-22 11:22:53

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. In a paper published in the April 19 issue of Molecular Cancer Therapeutics, a team led by Nancy Klauber-DeMore, MD, professor of surgery and a member of UNC Lineberger Comprehensive Cancer Center, used a monoclonal antibody to target SFRP2 expressed in cells from triple-negative breast...

2013-04-10 08:31:36

VANCOUVER, British Columbia and MENLO PARK, Calif., April 10, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. during a clinical poster session entitled, "A Phase...

2013-04-04 08:28:39

Dr. Stephen Keefe to present clinical data demonstrating CRLX101's combinability with Avastin® to treat renal cell carcinoma CAMBRIDGE, Mass., April 4, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that researchers will present both pre-clinical and clinical data on Cerulean's Phase 2 candidate, CRLX101, in sessions at the American Association for Cancer Research (AACR) Annual Meeting. Among the findings,...

2013-04-02 12:30:07

DUBLIN, April 2, 2013 /PRNewswire/ -- Research and Markets) has announced the addition of the "Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013" report to their offering      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is...

2013-03-22 08:24:51

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire/ -- Cerulean Pharma Inc. today announced that a randomized Phase 2b study of its experimental cancer treatment, CRLX101, in patients with advanced non-small cell lung cancer (NSCLC) did not meet its primary efficacy endpoint, overall survival benefit. Consistent with earlier clinical trials, CRLX101 showed signals of activity, including tumor reductions that meet RECIST criteria, and a favorable safety profile. CRLX101 is being studied in four...

2013-03-11 08:26:59

INCLINE VILLAGE, Nev., March 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in royalty revenues is driven by increased fourth quarter 2012 sales for all licensed...